We have established a Committee of Advisors (Board Members) with international profiles, who advise the management team on strategy, business development and commercialization
Scientific Advisory Board
Dr. Jaume Reventós
Chairman and Associate Professor of Cell Biology, Research Unit in Biomedicine and Translational Oncology Vall d’Hebron Research Institute and Hospital Barcelona. Jaume Reventós holds an MD degree (Autonomous University of Barcelona, School of Medicine, 1977), and was trained as medical resident in Clinical Chemistry (Hosp. Vall d’Hebrón, 1978-82). Graduate student . (INSERM, U-162, Lyon, France, 1982-84), and Ph.D. in Cell Biology (1984). Postdoctoral Fellow at the Rockefeller University (The Population Council), New York, USA (1985-88) ; and Assistant Professor at the Brookdale Center for Molecular Biology and Department of Obstetrics and Gynecology, at the Mount Sinai School of Medicine, New York (1988-90). Since october 1990, he is Chairman of the Biomedical Research Unit (Translational Oncology Laboratory) at the Vall d’Hebrón Research Institute and Hospital, where he leads a competitive translational research program in the molecular bases of hormone-dependent cancers, in particular, prostate, ovarian and endometrial cancers. From 2003 to 2009, he was President of the Catalan Society of Biology at the Catalan National Academy of Sciences and Associate Professor of Gynecology (since 2005) and of Cell Biology since 2009 at the Autonomous University of Barcelona, School of Medicine. In 2007 he graduated at the Program of Management Development (PMD) at the IESE School of Business, University of Navarra, Spain. In the recent years, the research of the group is focused in the characterization of genomic and proteomic differential profiles in cancer tissues and biological fluids in order to identify molecular markers and targets in the above mentioned tumors. To achieve these goals, the group is working in close collaboration with biotechnology companies.
Antoni Castells, MD, PhD (Clinical)
Dr. Antoni Castells, a specialist in Medicine and Surgery-Gastroenterology is the current director of Digestive and Metabolic diseases at Hospital Clinic in Barcelona and Coordinator of early detection of colorectal cancer program in Barcelona. As Gastrointestinal and Pancreatic oncology Group Director at CIBER network he led several research projects in colorectal cancer and new screening strategies. He has published more than 250 manuscripts in prestigious National and International journals and more than 50 book chapters. Additionally, he is co-coordinator of International multi-centre studies in colorectal cancer such as EPICOLON and COLONPREV, both focused on colorectal cancer screening, and a member of International Digestive Cancer Alliance and the World Gastroenterology Organization Task Force on Digestive Oncology.
Ran Vigdor, MBA (Business Development)
Mr. Vigdor is a business and corporate development specialist with extensive entrepreneurial and international experience ranging across industries and technologies and he is currently the CEO of Haystackz LTD. Prior to joining Haystackz LTD, he held the positions of CEO of TCD Pharma (Valladolid, Spain) and Business Development Director in CRB (Madrid, Spain) and Strategic Alliance Director in BioCancell Therapeutics (Israel), a publicly traded biotechnology start-up, where he was responsible for business and corporate development as well as investor and public relationships. Mr. Vigdor holds a LL.B in Law and a B.A. in Business Administration from the Hebrew University of Jerusalem, Israel and an MBA from the IE Business School (Madrid, Spain), where he graduated first in his class.
Ferran Prat, (Scientific and Business)
Mr. Prat has extensive global expertise in the in vitro diagnostic sector, where he held several leading positions for more than 25 years, especially in cancer diagnostics and personalized medicine (therapy selection and patient monitoring). He spent most of his career at Dako where he was general manager/Vice president for Europe, the Americas and the Asia Pacific region. He was also responsible for Global Strategy Marketing and Corporate Business Development. Ferran expertise spans worldwide know-how across the entire value chain from development to commercialization. Recently he also served as Chief Operating Officer in a Personalized Medicine start-up, bringing an R & D Project to full registration readiness for out-licensing. He has a BSc in Pharmacy (Universidad de Barcelona, Spain) and a Master’s in Marketing. Currently, Mr. Prat is the Head of the Diagnostics Division at Laboratorios LETI.
Thomas Taapken, PhD.
Dr. Taapken has wide experience in diagnostic companies, such as Epigenomics AG where he served as the CEO. Dr. Taapken was working as the CEO of one of Amadix direct competitors with a deep expertise in fundraising, regulatory and commercialization in the CRC screening space. Throughout his career, he has been involved in numerous transactions spanning acquisitions, mergers, divestitures, as well as private and public offerings.
Carolina García Rizo, PhD, MBA.
Carolina has over 15 years of experience in growth and innovation consulting, leading and executing business plans and commercial sales operations in Biotech and Medical devices. She is specialized in molecular diagnostics in the areas of Oncology, GYN/OBS and Infectious Diseases. Carolina served as a leader in strategic planning, business development, product commercialization, markets evaluation, new market expansion, collaboration with business partners, and driving sustainable growth worldwide. She is Head of Business Development at ThermoFisher.